|
|
Article: Endo licenses rights to market acute migraine treatment Frova.
- Article from:
- Women's Health Weekly
- Article date:
- August 12, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 AUG 12 - (NewsRx.com & NewsRx.net) -- Endo Pharmaceuticals, Inc., a wholly owned subsidiary of Endo Pharmaceuticals Holdings, Inc., (ENDP), and Vernalis, plc, have entered into an agreement granting Endo the exclusive rights to market Vernalis's Frova (frovatriptan) in North America.
Launched in the U.S. in June 2002, Frova is indicated for the acute treatment of migraine headaches in adults.
Net sales of Frova in the U.S. were $37.5 million in 2003.
"Frova has differentiating features from other migraine products, including the longest half life in the triptan class and a very low reported recurrence rate in its clinical program," said ...